Conestoga Capital Advisors LLC Has $137.70 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Conestoga Capital Advisors LLC trimmed its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 3.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,641,273 shares of the medical instruments supplier's stock after selling 51,561 shares during the period. LeMaitre Vascular accounts for approximately 2.1% of Conestoga Capital Advisors LLC's holdings, making the stock its 19th largest position. Conestoga Capital Advisors LLC owned about 7.28% of LeMaitre Vascular worth $137,703,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Opal Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the 1st quarter valued at $26,000. NBC Securities Inc. bought a new position in LeMaitre Vascular during the first quarter valued at about $36,000. Smartleaf Asset Management LLC lifted its position in shares of LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC lifted its position in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 117 shares during the last quarter. Finally, Huntington National Bank boosted its stake in shares of LeMaitre Vascular by 64.9% during the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after acquiring an additional 455 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of recent analyst reports. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Finally, Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $97.83.

LeMaitre Vascular Price Performance

NASDAQ:LMAT traded up $0.09 during mid-day trading on Friday, hitting $81.78. The company's stock had a trading volume of 467,754 shares, compared to its average volume of 170,364. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 41.30, a P/E/G ratio of 2.16 and a beta of 0.83. The company has a current ratio of 16.49, a quick ratio of 13.83 and a debt-to-equity ratio of 0.48. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The stock has a fifty day moving average of $83.84 and a 200-day moving average of $89.62.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The company had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. The company's revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.44 earnings per share. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. LeMaitre Vascular's payout ratio is presently 40.40%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 18,733 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the sale, the chief executive officer now directly owns 1,873,651 shares of the company's stock, valued at approximately $158,829,395.27. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 100,000 shares of company stock valued at $8,556,857. 9.50% of the stock is currently owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.